Neurology Pharmacology Flashcards

1
Q

What is the societal impact of cognitive disorders?

A

28% of disease burden is mental health
1 in 4 affected each year
£70-100 billion is costs/year
There is few effective treatment options but extensive health and social impacts

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How are AMPA and NMDA receptors implicated in memory?

A

If apply APV (blocks NMDA receptor), this would block the induction of long-term potentiation
When AMPA cells are blocked only a small amount of LTP is produced but then it decays. AMPA cells are key to memory trace formation
The drug stopped the synapses from changing in strength, however it did not stop communication between pre and post synapses
This is because AMPA cells are also involved- depolarise the neurone and unblock the Mg2+
Once NMDA have been activated, Ca2+ flows through and triggers a pathway that trafficks additional AMPAR to the membrane and a stronger connection is formed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the synaptic tagging hypothesis?

A

Synaptic tagging suggests that, following learning, certain synapses are marked or tagged in a way that sequesters plasticity proteins and so enables the specificity of persistence
In weak stimulation still get tag but no proteins upregulated and thus the memory trace is not created
If a protein synthesis inhibitor (anisomycin) is added the LTP dissapears

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is optogenetics?

A

A neuroscience technique that involves using light to control cells that have been genetically modified to express opsins (light sensitive channels that response to specific wavelengths of light)
- Channelrhodopsin-2 (ChR2) and halorhodopsin (NpHR) are examples of opsins used in optogenetics.
- ChR2 responds to blue light by allowing positive ions to enter the cell, leading to depolarization, while NpHR responds to yellow light by allowing negative ions to enter, leading to hyperpolarization.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What does fear conditioning do to AMPA receptors?

A

Drives AMPA receptors into the synapse of a large fraction of postsynaptic neurones in the lateral amygdala, a brain structure essential for this learning process

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How are NMDA receptors involved in short and long term memory?

A

Using an NMDA receptor blocker AP5 on rats in a watermaze, it was found that short term memory for spatial information is independent of NMDA receptors and the rapid consolidation of spatial information into long-term memory requires activation of hippocampal NMDA receptors.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How can the Cre-Lox procedure be used for conditional gene deletion?

A

Cre is an enzyme derived from the bacteriophage P1. Cre recognises and acts on a specific DNA sequence called ‘LoxP sites’
The gene of interest is modified to induce loxP sites flanking critical regions
The gene is still functional when both loxP sites are present
Cre recombinase is placed under the control of a tissue specific or inducible promoter. This ensures cre is only expressed in specific cells or specific conditions
Cre recomination results in the exicision of the floxed region, allowing for conditional gene deletion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How can GFP be used in a molecular process?

A

GFP family can be used to label cells or cellular structures
Green fluorescent protein is a naturally occuring protein derived from a jellyfish
It has become a widely used molecular tool due to its fluorescence ability and its compatibility with living cells
To label cells with GFP, the gene encoding GFP is genetically fused to the gene of interest.
This fusion gene is then introduced into cells using various methods, such as transfection, viral transduction, or microinjection.
When exposed to specific wavelengths of light, GFP absorbs photons and emits green fluorescence. This fluorescence allows researchers to visualize he localization of the protein within the cell.
Allows visualisation of processes such as cell division, migration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is FRET?

A

Fluorescence resonance energy transfer
When the donor and the acceptor fluorphores are in close proximity (typically within 1-10 nanometers) the energy from the excited donor is transfered
FRET can be detected by changes in the fluorescence properties of the donor and acceptor.
By attaching donor and acceptor fluorophores to specific molecules of interest, FRET can be used to study protein-protein interactions, cellular signalling, molecular conformation changes and DNA.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is calcium imaging?

A

A technique used to visualise and monitor changes in intracellular calcium within living cells
Calcium imaging relies on the use of fluorescent calcium indicators. These are molecules that exhibit changes in fluorescence intensity or colour in response to binding with calcium ions.
Calcium imaging is typically performed using fluorescence microscopy. The fluorescent signals emitted by the calcium indicators are captured and recorded in real-time.
Common types of calcium indicators include small molecule dyes (such as Fluo-4, Fura-2, and Rhod-2) and genetically encoded calcium indicators (GECIs) like GCaMP (Genetically Encoded Calcium Indicator

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is chemogenetics?

A

The engineering of proteinn receptors to respond to previously unrecognised small molecules
- Chemogenetics often involves the use of designer receptors, which are engineered versions of naturally occurring receptors. These receptors are designed to respond selectively to synthetic ligands that do not interact with endogenous receptors.
- Genetically engineered to be introduced into the target cell
- To target specific cell populations the receptor gene is placed under the control of a tissue specific promoter

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How can neurones be activity tagged?

A

c-Fos is a immediate early gene that is rapidly expressed in neurones in response to activation.
This can be flurorescently labelled
c-Fos is placed under the control of the tet-on or tet off promoter, so can only be expressed when DOX is given or removed.
Cells that were activated in a time window can be identified

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the problem with activity tagging of neurones using tet on/off systems and how could this be overcome?

A

Tagging window is large so there is plenty oppurtunity for different memories to be formed and the wrong neurones tagged
Can use all optical interrogation of neural circuits. This detects activity of cells based on Ca2+ imaging, although this does not work on freely moving animals

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the financial and personal burden of mental health?

A

28% of disease burden is mental health with 1 in 4 people affected each year. Costs an estimated £70-100 billion each year

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What drugs are amnesic agents?

A
  • Procedures or chemicals that cause memory impairment.
  • Examples are electroconvulsive shock (ECS), beta-adrenergic receptor antagonist (propranolol), protein synthesis inhibitors (anisomycin), anaesthetics (MS222)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How many propanolol be used in neurology?

A

The beta-adrenergic blocker propranolol given within hours of a psychologically traumatic event reduces physiologic responses during subsequent mental imagery of the event- PTSD
Oral propanolol administered prior to nictotine unconditioned stimulus induced memory (i.e. being reexposed to nicotine) decreased craving in humans

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is general cognitive function (measured within labs) useful for?

A

There is a correlation between general cognitive function and job performance
There is an increased risk of mortality for all diseases inversely linked with cognitive ability
Laboratory cognitive tests were found to strongly relate to everyday knowledge tasks such as knowledge about medication and memory for household items

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What are the pros and cons of studying aging in a cross section vs longitudional study?

A
  • Can measure a wide range of people of all ages once- cross sectional.
    • However aging is a dynamic within-person phenomenon
    • And cohort differences (Flynn effect- over the last century people have performed better on cognitive tests than previous generations)
  • Or can follow a group of people in a
    longitudinal
    • Nonrandom attrition (bias against people less healthy)
    • Practise effects of remembering previous tests given over the lifetime
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is the lothian birth cohort?

A

The lothian birth cohort 1936 is a longitudinal research project that focuses on individuals born in Edinburgh
Participants in the LBC1936 underwent a battery of cognitive tests to assess various aspects of cognitive function, including memory, processing speed, reasoning, and other domains. These assessments were conducted at multiple time points, allowing researchers to track changes in cognitive abilities over time (started age 11)
In addition to cognitive assessments, the LBC1936 collected various biomedical and genetic data from participants. This includes information on health, lifestyle, and genetic factors, providing a comprehensive dataset for researchers to analyze.
Some participants in the LBC1936 underwent structural and functional brain imaging, such as magnetic resonance imaging (MRI). Brain imaging data contribute to a better understanding of the neural correlates of cognitive aging.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What are the statistics for depression?

A

4% global average
It is second in global health burden (after heart disease), and the 4th leading cause of mortality in younger people.
It also varies by socioeconomic status- higher in those with low socioeconomic status.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What is depression?

A

Depression is a common but serious mood disorder. It causes severe symptoms that affect how a person feels, thinks, and handles daily activities, such as sleeping, eating, or working.
To be diagnosed with depression, the symptoms must be present for at least 2 weeks.
Symptoms include depressed mood, lack of motivation, change in appetite, isomnia, fatigue and poor self esteem

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What is thought to cause depression?

A

Monoamine dysfunction- deopamine, norepinepherine and seronin.
Dopamine is involved in reward and motivation, norepinephrine in alertness and serotonin in mood
Also different theories such as lower BDNF levels, impaired synpatic function and plasticity
Also strong links between inflammation and depression- direction unknown however increased levels of TNF-alpha have been associated with depressive behaviour in animal studies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What is the first line treatment for depression, what is the evidence and what are side effects?

A

SSRIs- selective serotonin reuptake inhibitors
Reduce the reuptake of serotonin from the synapse thus making more serotonin available in the synapse.

Recent evidence shows in mice treated with LPS, SSRIs administration leads to decreased serum levels of TNF-alpha and IL-10

Do have side effects that need to be considered- gastrointestinal problems, sleep disturbances and sexual dysfunction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What can PET scans be used for in neurology?

A

Can measure and track synapse loss using a tracer that binds to the synaptic vesicle glycoprotein
Anti-body tracers also been developed- can visualise the build up of pathology (amyloid beta or tau for example) in the brain.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

What are the 5 cardinal signs of inflammation?

A

Heat, pain, redness, swelling, loss of function

26
Q

What are cytokines and what are examples?

A

Cytokines= produced by immune cells, play a crucial role in cell signalling.
Common categories include interleukins, chemokines, tumour necrosis factors and interferons.
- They can stimulate or inhibit immune cell activation, proliferation, and differentiation. For example, interleukin-2 (IL-2) promotes the proliferation of T cells, a type of immune cell.
- Another example, IL-6 is a pro-inflammatory cytokine and plays a central role in the initiation and amplification of inflammatory responses. Produced by a variety of immune cells

27
Q

What is neuroinflammation?

A

Inflammation of the CNS
Mediated by microglia which detect PAMPs/DAMPs via pattern recognition receptors and release cytokines
When their response is chronic it causes problems such as neurodegeneration, BBB damage.

28
Q

What are the clinical consequences of neuroinflammation?

A

Debate over whether neuroinflammation causes or is a consequence of AD
Implicated in a wide range of diseases such as depression, dementia, lupus and stroke

29
Q

What evidence is there that chronic inflammation contributes to neurdegenerative brain changes?

A

DNA methylation of CRP is associated with total brain volume, grey and white matter volume and atrophy
We also find that DNAm CRP has an inverse association with global and domain-specific (speed, visuospatial, and memory) cognitive functioning
These results support the hypothesis that chronic inflammation may contribute to neurodegenerative brain changes that underlie differences in cognitive ability in later life
Role for an anti-inflammatory lifestyle such as anti-smoking and alcohol and obesity

30
Q

What is the evidence for neuroinflammation as a cause or consequence of AD disease?

A

CONSEQUENCE- injection of AB in rats caused increased activation of microglia.
In cultured human vascular cells, it was discovered that stimulation of Aβ dose-dependently increased CD40, IFN-gamma and IL-1β expression in endothelial cells
CAUSE- Treatment with pro-inflammatory mediators such as interferon gamma promoted the cleavage of the Aβ precursor molecule APP into Aβ in human cell cultures
Non-steroidal anti-inflammatory drugs (NSAIDs) can reduce Aβ deposition and memory impairment in a mice model of AD when taken in early disease stages (Woodling et al., 2016).
In humans, NSAIDs and anti-inflammatory diets such as Mediterranean protect against developing AD

31
Q

What is important when choosing an animal model to study disease?

A

Construct validity- whether or not the model reflects the cause of the disease
Face validity- does the model show features that would be seen in humans e.g. decreased socialibility
Predictive validity- can the model be used to predict the outcome of a treatment

32
Q

What are the current therapies for ASD/

A

To date there is no specific treatments for ASD and currently pharmacological therapies are symptomatic e.g. anticonvulsants for seizures and melatonin for sleep disturbances
New therapies are arising- cell therapies and gene therapies

33
Q

How are cell therapies potentially used to treat ASD?

A

Neuroinflammation is increasingly linked to ASD- - Hematopoietic stem cell therapies can prevent neurodegeneration, reduce the pro inflammatory state and thus prolong the life of people will ASD
- Obtained from foetal stem cells and autologous cord blood.
- Mesenchymal stem cell transplantation in which cells that secrete extracellular vesicles and can mediate inter-cell communication are transplanted. These can alter the phenotype of activated microglia and secrete growth factors.
Still a major challenge for actually translation into practise

34
Q

How can gene therapy potentially be used in ASD?

A

Novel MECP2 gene therapy is effective in a multicenter study using two mouse models of Rett syndrome and is safe in non-human primates. it reversed the robudt phenotype in mice
Nov 30th 2023= the dosing of the first two female pediatric patients with Rett syndrome in its ongoing Phase 1/2 trial of NGN-401
Still hard to implement delivery methods that have a higher efficacy in crossing the BBB

35
Q

What is an example a CRISPR mediatiated modifications that might be useful in neuro diseases?

A

CRISPR can be used to remove the NAT that is blocking the expression of the paternal copy of the UBE3A NAT. Useful in angleman syndrome, which is caused by maternal inactivation of that gene
NATs= Natural antisense transcripts = small molecules of RNA that modulate/ block the expression of genes. Can remove them to allow the expression of the gene.
Angleman syndrome= seizures, intellectual disability, happy demeanor

36
Q

What drug can be used to treat fragile X syndrome?

A

Early treatment of Lovastatin in FXS (immediately after weaning) it had positive effects- increases context recognition and increases reaction to the tickle test. It is able to correct submissive behaviour
we observe no regression of cognitive performance in the FXS rats over several months after treatment

Also cannabidivarin can be given immediatly after weaning to ameliorate symptoms

Behavioral tests assessing FXS-like abnormalities included anxiety, locomotor, cognitive, social and sensory alterations.

Key symptoms of fragile X- Developmental disabilities, learning problems and social and behaviour problems

37
Q

What is Cannabidivarin?

A

Cannabidivarin is a non-intoxicating psychoactive cannabinoid found in Cannabis.
It is a homolog of cannabidiol (CBD), with the side-chain shortened by two methylene bridges (CH2 units).

38
Q

What is dementia?

A

A chronic disorder of the mental disorders caused by disease or injury and marked by memory disorders, personality changes and impaired reasoning
It is an umbrella term for different conditions such as AD, vascular disease, Lewy Body Dementia and Fronto-temporal dementia

39
Q

What dementia drug was introduced in the 1980s?

A

Cholinesterase inhibitors such as tacrine were introduced for AD.
These medications aimed to enhance cholinergic neurotransmission (increases ACh)
Helps to manage symptoms such as memory, thinking, language, judgment
Now donepezil is approved for all stages of AD
Though generally well-tolerated, if side effects occur, they commonly include nausea, vomiting, loss of appetite and increased frequency of bowel movements.

40
Q

When was the first disease modifying drug approved for AD disease?

A

2023- LECANEMAB
It is a monoclonal antibody designed to target and remove beta-amyloid plaques
Lecanemab works by binding to beta-amyloid aggregates, specifically targeting soluble and insoluble forms of beta-amyloid. The goal is to facilitate the clearance of beta-amyloid plaques from the brain.
It slows progression but still is not a cure

41
Q

What are the statistics for dementia?

A

45 million people worldwide living with dementia
Same amount of money as the GDP of Denmark spent worldwide on dementia

42
Q

What are dementias caused by?

A

Proteinopathies
Apart from vascular dementia

43
Q

What are risk factors for dementia?

A

APOE4 gene- involved in lipid metabolism. Also known to bind to AB and is involved it clearance
Smoking, alcohol, obesity
Social isolation
Depression

44
Q

What drug is associated with a reduced risk of AD?

A

Statins- by 50%
May be due to environmental risk factors

45
Q

What brain changes occur in AD disease?

A

Brain atrophy, amyloid-beta plaques, tau tangles
Also accompanied by synapse loss, cytokine secretion, loss of oligodendrocytes, myeline damage and BBB breakdown
Inflammation also common

46
Q

What are amyloid directed immunotherapies?

A

Monoclonal antibodies that slow disease progression
- Aducanumab: designed to target beta-amyloid plaques and facilitate their clearance.
- Aducanumab underwent several clinical trials, including Phase 3 trials named EMERGE and ENGAGE, to assess its safety and efficacy.
- The results of these trials were initially mixed, with one study (EMERGE) showing a reduction in clinical decline, while the other study (ENGAGE) did not meet its primary endpoint.
- The approval was based on data from the EMERGE trial, which showed a reduction in amyloid plaques and a potential slowing of cognitive decline. However, the decision was controversial, as some experts and scientists raised concerns about the robustness of the evidence and the overall clinical benefit.
Also Lecanemab

47
Q

What is the success rate for disease modifying therapies for AD?

A

Over the past 20 years, 99% of clinical trials for disease modifying therapies for AD have failed

48
Q

Where do the immunotherapies against AD bind to?

A

Donanemab, lecanemab and aducanumab

49
Q

What are the negatives of current immunotherapies used to treat AD?

A

Both donemab and lecanemab come with risks for serious and even fatal brain swelling and bleeding
Very expensive
Minor symptoms are seen such as headache and fatigue
Brain bleeds 3 people died in the 2 trials out of 1000-2000 people.
Need to have a monthly infusion and MRIs
Not currently approved for NHS use

50
Q

What therapeutics are currently being used to target tau tangles?

A

The limited success of Aβ-targeting therapies led to a change in focus towards the tau protein
Two active vaccines, nine antibodies, are currently in clinical trials
Tau antisense oligonucleotides- a phase Ib trial targeting MAPT mRNA was found to be safe and reduce total tau in a dose-dependent manner

51
Q

What two conditions are linked by O9orf72 mutations?

A

ALS- Amyotrophic lateral sclerosis, Progressive loss of muscle innervation (neurodegeneration) leads to muscle atrophy.
FTD- fronto-temporal dementia, changes related to behaviour, personality or language

52
Q

How does C9orf72 contribute to ALS?

A
  • The most common mutation in the C9orf72 gene is a hexanucleotide repeat expansion of the GGGGCC sequence. In affected individuals, this repeat expansion can occur hundreds to thousands of times, leading to abnormal RNA and protein products.
  • The expanded repeat region can form abnormal RNA aggregates known as RNA foci. These foci may sequester RNA-binding proteins, disrupting normal cellular functions and potentially contributing to neurodegeneration.
53
Q

What are the treatment options for ALS?

A

Riluzole= The exact mechanism of action of riluzole in ALS is not fully understood. However, it is thought to modulate glutamate, an excitatory neurotransmitter, by inhibiting its release. Excessive glutamate levels are believed to contribute to the excitotoxicity observed in ALS, leading to damage to motor neurons.
- First drug commercially available to treat ALS.
- Extends lifespan by approximately 3 months.

Edaravone= The exact mechanism of action of edaravone in ALS is not fully understood. However, it is believed to have antioxidant and anti-inflammatory properties.
- Approved by FDA in 2017.
- Has shown some evidence of improved function, however, less conclusive evidence of
efficacy

54
Q

What evidence is there that inflammation contributes to dementia?

A
  • Sipila et al 2021 did a study assessing the association between hospital-treated infection and dementia risk in 700,000 individuals
  • Found a dose dependant increased risk for all dementia forms, irrespective of microbial aetiology
  • “In conclusion, our findings support the hypothesis that associations between infectious diseases and dementia are attributable to general inflammation rather than to specific microbes or infections in the CNS .”

Also, the ARIC study measured blood markers of systemic inflammation e.g. CRP and cognitive function over 30 years. Elevated inflammation composite score, CRP level, or greater number of elevated inflammatory markers during midlife caused a steeper cognitive decline over a 20-year period. The effect was independent of potentially confounding variables e.g. stroke or APOE4 genotype

55
Q

How are microglia implicated in AD disease?

A

The presence of AB, drives inflammation cytokine secretion from microglia. Microglia expression NLRP3 inflammasome and if components are knocked out of this it can stop AD pathology and lessen memory deficits in mouse AD models
PET scans can also show Translocator protein (TSPO) induced on reactive microglia/macrophages.
ncreased TSPO binding is also evident in patients with mild cognitive impairment i.e. inflammation is likely initiated early in disease course and may become chronically progressive
This inflamamtion can contribute to more AB plaques, dysfunctional astrocytes and microglia (microglia will not prune useless synpases as they usually do in healthy disease)

56
Q

How might microglia be targeted to treat AD?

A

Anti-inflammatory treatment not shown to improve patient outcomes in phase 3 clinical trials so far
Two phase II anti-inflammatory drugs= canakinumab (anti-IL-1 mAb) and baricitinib (JAK inhibitor/ anti-interferon)

57
Q

What is Huntington’s disease?

A

Caused by dominant mutation in the Huntington gene.
Causes huge degeneration of the striatum, which leads to involuntary movements, cognitive decline and mental health disorders

58
Q

What can rescue the HD mouse phenotype?

A

Expressing Gi GPCRs within astrocytes and activating them
Genes get unregulated, correction of astrocytic, synaptic and behvioural phenotypes
Number of spines rescued by Gi pathway
Potential treatment option

59
Q

What diseases are affected by lack of myelination?

A

Multiple sclerosis
ASD- found to have varying levels of myeline
Myeline defects in neurodevelopmental animal disorders such as Pitt-Hopkins syndrome
Huntington’s disease

60
Q

What drug could potentially be used to remyelinate the brain?

A

Metformin Restores CNS Remyelination Capacity by Rejuvenating Aged Stem Cells,
Aged oligodendrocyte proginator cells become unresponsive to pro-differentiation signals
Aged OPCs treated with metformin regain responsiveness to pro-differentiation signals

61
Q

What gene therapy is currently being trialled to treat huntington’s disease?

A

The antisense oligonucleotide tominersen was designed to slow the progression of Huntington’s disease by lowering levels of huntingtin gene (HTT) products, including mutant huntingtin protein (HTT).
Phase 3 trial- given every 8 weeks symptoms were significantly worse than the placebo group
Given every 16 weeks there was no difference
The changes in mutant HTT levels in CSF were consistent with dose regimen–dependent decreases and concomitant increases in ventricular volume- unknown why but authors hypothesis it is due to reduced absorbsion of CSF

62
Q

How does stroke effect cognitive function?

A

Stroke doubles the risk of developing dementia and 56% of patients report cognitive dysfunction at 6 months post stroke (30% develop dementia)

Although it is hard to compare cognitive abilities before and after stroke- not often documented

Preclinical models with Y mazes show that post stroke there is a decreased cognitive ability